Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging paradigms in targeted treatments for Asian patients with NSCLC.

Expert opinion on pharmacotherapy - 1 Jun 2015

Ke E-E, Zhou Qing, Wu Yi-Long

Abstract excerpt

INTRODUCTION: EGFR-targeted drugs have been successfully approved in many countries and have demonstrated higher efficacy and lower toxicity than chemotherapy in molecularly defined subgroups of patients. Significant advances in clinical trials and studies focusing on targeted therapies have rapi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Clinical Trials, Phase III as Topic
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Fusion

Share to Molecular Targeted Therapy

Share to Neoadjuvant Therapy

Share to Protein Kinase Inhibitors

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 25907450
DOI: 10.1517/14656566.2015.1040391

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25907450-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging paradigms in targeted treatments for Asian patients with NSCLC.PMID 25907450Read ↗

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinionSemantic proximity Read ↗

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.Semantic proximity Read ↗

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia.Semantic proximity Read ↗

Targeted therapeutic options in early and metastatic NSCLC-overview.Semantic proximity Read ↗

Common EGFR -Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy.Semantic proximity Read ↗

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.Semantic proximity Read ↗

Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patientsSemantic proximity Read ↗

A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological studySemantic proximity Read ↗

Novel targeted agents for the treatment of lung cancer in China.Semantic proximity Read ↗

Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies.Semantic proximity Read ↗

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.